Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021

被引:1510
作者
Ong, Kanyin Liane [1 ]
Stafford, Lauryn K. [1 ]
Mclaughlin, Susan A. [1 ]
Boyko, Edward J. [2 ,9 ]
Vollset, Stein Emil [1 ,3 ]
Smith, Amanda E. [1 ]
Dalton, Bronte E. [1 ]
Duprey, Joe [1 ]
Cruz, Jessica A. [1 ]
Hagins, Hailey [1 ]
Lindstedt, Paulina A. [1 ]
Aali, Amirali [10 ]
Abate, Yohannes Habtegiorgis [19 ]
Abate, Melsew Dagne [20 ]
Abbasian, Mohammadreza [32 ]
Abbasi-Kangevari, Zeinab [33 ,45 ]
Abbasi-Kangevari, Mohsen [21 ,45 ]
Abd ElHafeez, Samar [68 ]
Abd-Rabu, Rami [70 ]
Abdulah, Deldar Morad [72 ]
Abdullah, Abu Yousuf Md [73 ]
Abedi, Vida [75 ,76 ]
Abidi, Hassan [77 ]
Aboagye, Richard Gyan [79 ]
Abolhassani, Hassan [46 ,80 ]
Abu-Gharbieh, Eman [81 ]
Abu-Zaid, Ahmed [88 ,90 ]
Adane, Tigist Demssew [91 ]
Adane, Denberu Eshetie [95 ]
Addo, Isaac Yeboah [98 ,100 ]
Adegboye, Oyelola A. [101 ]
Adekanmbi, Victor [103 ]
Adepoju, Abiola Victor [105 ,106 ]
Adnani, Qorinah Estiningtyas Sakilah [107 ]
Afolabi, Rotimi Felix [109 ]
Agarwal, Gina [115 ]
Aghdam, Zahra Babaei [116 ]
Agudelo-Botero, Marcela [121 ]
Arriagada, Constanza Elizabeth Aguilera [124 ]
Agyemang-Duah, Williams [125 ]
Ahinkorah, Bright Opoku [126 ]
Ahmad, Danish [128 ,129 ]
Ahmad, Rizwan [130 ]
Ahmad, Sajjad [132 ]
Ahmad, Aqeel [133 ]
Ahmadi, Ali [34 ,135 ]
Ahmadi, Keivan [138 ]
Ahmed, Ayman [142 ,143 ]
Ahmed, Ali [141 ,144 ]
Ahmed, Luai A. [145 ]
机构
[1] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Seattle, WA USA
[3] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA USA
[4] Univ Washington, Dept Appl Math, Seattle, WA 98195 USA
[5] Univ Washington, Div Plast & Reconstruct Surg, Seattle, WA 98195 USA
[6] Univ Washington, Dept Med, Seattle, WA USA
[7] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
[8] Univ Washington, Div Biomed & Hlth Informat, Seattle, WA 98195 USA
[9] Dept Vet Affairs, Gen Med Serv, Seattle, WA USA
[10] Mashhad Univ Med Sci, Fac Med, Mashhad, Razavi Khorasan, Iran
[11] Mashhad Univ Med Sci, E Learning Ctr, Mashhad, Razavi Khorasan, Iran
[12] Mashhad Univ Med Sci, Clin Res Dev Unit, Mashhad, Razavi Khorasan, Iran
[13] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran
[14] Mashhad Univ Med Sci, Int UNESCO Ctr Hlth Related Basic Sci & Human Nut, Mashhad, Razavi Khorasan, Iran
[15] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Razavi Khorasan, Iran
[16] Mashhad Univ Med Sci, Biotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran
[17] Mashhad Univ Med Sci, Dept Med Informat, Mashhad, Razavi Khorasan, Iran
[18] Mashhad Univ Med Sci, Clinial Res Dev Unit, Mashhad, Razavi Khorasan, Iran
[19] Aleta Wondo Hosp, Dept Clin Governance & Qual Improvement, Aleta Wondo, Ethiopia
[20] Woldia Univ, Dept Nursing, Woldia, Ethiopia
[21] Harvard Univ, Dept Orthoped Surg, Boston, MA 02115 USA
[22] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA
[23] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA
[24] Harvard Univ, Ctr Primary Care, Boston, MA 02115 USA
[25] Harvard Univ, Dept Environm Hlth, Boston, MA 02115 USA
[26] Harvard Univ, Div Cardiol, Boston, MA 02115 USA
[27] Harvard Univ, Maternal Fetal Care Ctr, Boston, MA 02115 USA
[28] Harvard Univ, Cardiovasc Dept, Boston, MA 02115 USA
[29] Harvard Univ, Dept Hlth Policy & Oral Epidemiol, Boston, MA 02115 USA
[30] Harvard Univ, Dept Global Hlth & Populat, Boston, MA 02115 USA
[31] Harvard Univ, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[32] Shahid Beheshti Univ Med Sci, Orthopaed Surg, Tehran, Iran
[33] Shahid Beheshti Univ Med Sci, Social Determinants Hlth Res Ctr, Tehran, Iran
[34] Shahid Beheshti Univ Med Sci, Dept Epidemiol, Tehran, Iran
[35] Shahid Beheshti Univ Med Sci, Natl Nutr & Food Technol Res Inst, Tehran, Iran
[36] Shahid Beheshti Univ Med Sci, Psychiat Nursing & Management Dept, Tehran, Iran
[37] Shahid Beheshti Univ Med Sci, Obes Res Ctr, Tehran, Iran
[38] Shahid Beheshti Univ Med Sci, Funct Neurosurg Res Ctr, Tehran, Iran
[39] Shahid Beheshti Univ Med Sci, Dept Genet, Tehran, Iran
[40] Shahid Beheshti Univ Med Sci, Sch Med, Tehran, Iran
[41] Shahid Beheshti Univ Med Sci, Dept Biol & Anat Sci, Tehran, Iran
[42] Shahid Beheshti Univ Med Sci, Ophthalm Epidemiol Res Ctr, Tehran, Iran
[43] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran
[44] Shahid Beheshti Univ Med Sci, Med Eth & Law Res Ctr, Tehran, Iran
[45] Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, Iran
[46] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Tehran, Iran
[47] Univ Tehran Med Sci, Sch Med, Tehran, Iran
[48] Univ Tehran Med Sci, Dept Sci Res, Tehran, Iran
[49] Univ Tehran Med Sci, Endocrinol & Metab Res Inst, Tehran, Iran
[50] Univ Tehran Med Sci, Dept Surg, Tehran, Iran
基金
英国惠康基金;
关键词
LIFE-STYLE INTERVENTION; MIDDLE-INCOME COUNTRIES; INDIVIDUAL-LEVEL DATA; TERM-FOLLOW-UP; RISK-FACTORS; BARIATRIC SURGERY; PREVENTION; GLUCOSE; MORTALITY; OBESITY;
D O I
10.1016/S0140-6736(23)01301-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), we produced location-specific, age-specific, and sex-specific estimates of diabetes prevalence and burden from 1990 to 2021, the proportion of type 1 and type 2 diabetes in 2021, the proportion of the type 2 diabetes burden attributable to selected risk factors, and projections of diabetes prevalence through 2050. Methods Estimates of diabetes prevalence and burden were computed in 204 countries and territories, across 25 age groups, for males and females separately and combined; these estimates comprised lost years of healthy life, measured in disability-adjusted life-years (DALYs; defined as the sum of years of life lost [YLLs] and years lived with disability [YLDs]). We used the Cause of Death Ensemble model (CODEm) approach to estimate deaths due to diabetes, incorporating 25 666 location-years of data from vital registration and verbal autopsy reports in separate total (including both type 1 and type 2 diabetes) and type-specific models. Other forms of diabetes, including gestational and monogenic diabetes, were not explicitly modelled. Total and type 1 diabetes prevalence was estimated by use of a Bayesian meta-regression modelling tool, DisMod-MR 2.1, to analyse 1527 location-years of data from the scientific literature, survey microdata, and insurance claims; type 2 diabetes estimates were computed by subtracting type 1 diabetes from total estimates. Mortality and prevalence estimates, along with standard life expectancy and disability weights, were used to calculate YLLs, YLDs, and DALYs. When appropriate, we extrapolated estimates to a hypothetical population with a standardised age structure to allow comparison in populations with different age structures. We used the comparative risk assessment framework to estimate the risk-attributable type 2 diabetes burden for 16 risk factors falling under risk categories including environmental and occupational factors, tobacco use, high alcohol use, high body-mass index (BMI), dietary factors, and low physical activity. Using a regression framework, we forecast type 1 and type 2 diabetes prevalence through 2050 with Socio-demographic Index (SDI) and high BMI as predictors, respectively. Findings In 2021, there were 529 million (95% uncertainty interval [UI] 500-564) people living with diabetes worldwide, and the global age-standardised total diabetes prevalence was 6 center dot 1% (5 center dot 8-6 center dot 5). At the super-region level, the highest age-standardised rates were observed in north Africa and the Middle East (9 center dot 3% [8 center dot 7-9 center dot 9]) and, at the regional level, in Oceania (12 center dot 3% [11 center dot 5-13 center dot 0]). Nationally, Qatar had the world's highest age-specific prevalence of diabetes, at 76 center dot 1% (73 center dot 1-79 center dot 5) in individuals aged 75-79 years. Total diabetes prevalence-especially among older adults-primarily reflects type 2 diabetes, which in 2021 accounted for 96 center dot 0% (95 center dot 1-96 center dot 8) of diabetes cases and 95 center dot 4% (94 center dot 9-95 center dot 9) of diabetes DALYs worldwide. In 2021, 52 center dot 2% (25 center dot 5-71 center dot 8) of global type 2 diabetes DALYs were attributable to high BMI. The contribution of high BMI to type 2 diabetes DALYs rose by 24 center dot 3% (18 center dot 5-30 center dot 4) worldwide between 1990 and 2021. By 2050, more than 1 center dot 31 billion (1 center dot 22-1 center dot 39) people are projected to have diabetes, with expected age-standardised total diabetes prevalence rates greater than 10% in two super-regions: 16 center dot 8% (16 center dot 1-17 center dot 6) in north Africa and the Middle East and 11 center dot 3% (10 center dot 8-11 center dot 9) in Latin America and Caribbean. By 2050, 89 (43 center dot 6%) of 204 countries and territories will have an age-standardised rate greater than 10%. Interpretation Diabetes remains a substantial public health issue. Type 2 diabetes, which makes up the bulk of diabetes cases, is largely preventable and, in some cases, potentially reversible if identified and managed early in the disease course. However, all evidence indicates that diabetes prevalence is increasing worldwide, primarily due to a rise in obesity caused by multiple factors. Preventing and controlling type 2 diabetes remains an ongoing challenge. It is essential to better understand disparities in risk factor profiles and diabetes burden across populations, to inform strategies to successfully control diabetes risk factors within the context of multiple and complex drivers. Funding Bill & Melinda Gates Foundation. Copyright (c) 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. June S0140-6736(23)01301-6 *Collaborators end Correspondence and Seattle, ongl@uw.edu
引用
收藏
页码:203 / 234
页数:32
相关论文
共 94 条
[1]   Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review [J].
Afroz, Afsana ;
Alramadan, Mohammed J. ;
Hossain, Md Nassif ;
Romero, Lorena ;
Alam, Khurshid ;
Magliano, Dianna J. ;
Billah, Baki .
BMC HEALTH SERVICES RESEARCH, 2018, 18
[2]  
Afshin A, 2017, NEW ENGL J MED, V377, P1496, DOI 10.1056/NEJMc1710026
[3]   Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis [J].
Aggarwal, Gaurav ;
Lippi, Giuseppe ;
Lavie, Carl J. ;
Henry, Brandon Michael ;
Sanchis-Gomar, Fabian .
JOURNAL OF DIABETES, 2020, 12 (11) :851-855
[4]   Type 2 diabetes [J].
Ahmad, Ehtasham ;
Lim, Soo ;
Lamptey, Roberta ;
Webb, David R. ;
Davies, Melanie J. .
LANCET, 2022, 400 (10365) :1803-1820
[5]  
Alluhidan M., 2022, Overweight and Obesity in Saudi Arabia Consequences and Solutions
[6]   Semaglutide for the treatment of overweight and obesity: A review [J].
Bergmann, Natasha Chidekel ;
Davies, Melanie J. ;
Lingvay, Ildiko ;
Knop, Filip K. .
DIABETES OBESITY & METABOLISM, 2023, 25 (01) :18-35
[7]  
Bhutta ZA, 2021, LANCET, V398, P1837, DOI 10.1016/S0140-6736(21)02247-9
[8]   Obesity: global epidemiology and pathogenesis [J].
Blueher, Matthias .
NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (05) :288-298
[9]   Capillary versus venous bedside blood glucose estimations [J].
Boyd, R ;
Leigh, B ;
Stuart, P .
EMERGENCY MEDICINE JOURNAL, 2005, 22 (03) :177-179
[10]   Diabetes mellitus, race, and socioeconomic status - A population based study [J].
Brancati, FL ;
Whelton, PK ;
Kuller, LH ;
Klag, MJ .
ANNALS OF EPIDEMIOLOGY, 1996, 6 (01) :67-73